US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Conduit Pharmaceuticals Inc.

0.6201

-0.1600-20.51%

Post-market: 0.6148-0.0053-0.85%19:59 EDT

Volume:1.47M

Turnover:927.80K

Market Cap:4.13M

PE:-0.03

High:0.6695

Open:0.6400

Low:0.6001

Close:0.7801

Loading ...

Overview Company News Filings

BRIEF-Conduit Pharmaceuticals Announces Leadership Changes

BRIEF-Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For Vtama®

Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects

Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program

THOMSON REUTERS

Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program

BRIEF-Conduit Pharmaceuticals Expands Partnership With Sarborg Limited

Conduit expands parntership with Sarborg

Conduit Pharmaceuticals Expands Partnership With Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization

THOMSON REUTERS

Conduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization

Conduit Pharmaceuticals Inc - Secures Composition of Matter Patent From Uspto for Azd1656

THOMSON REUTERS

Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

Oxbridge / SurancePlus to Speak at Uncorrelated Puerto Rico on April 1st

Conduit Pharmaceuticals provides R&D upgrade on AZD1656, AZD5658, AZD5904

Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets Azd1656, Azd5658, and Azd5904

THOMSON REUTERS

Conduit Pharmaceuticals - Results for Study With Charles River Laboratories Expected in Q2 2025

THOMSON REUTERS

Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904

Is Conduit Pharmaceuticals Inc. (CDT) the Best Micro Cap Stock to Buy Now?

Conduit Pharmaceuticals Gets Nasdaq Extension, Plans Capital Market Transfer

MT Newswires Live

Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel

THOMSON REUTERS

BRIEF-Conduit Pharmaceuticals Files For Offering Of Up To $17.8 Million Of Shares Of Common Stock - SEC Filing

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CDT/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CDT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CDT\",,,,,undefined,":{"symbol":"CDT","market":"US","secType":"STK","nameCN":"Conduit Pharmaceuticals Inc.","latestPrice":0.6201,"timestamp":1744920000000,"preClose":0.7801,"halted":0,"volume":1466988,"hourTrading":{"tag":"盘后","latestPrice":0.6148,"preClose":0.6201,"latestTime":"19:59 EDT","volume":63320,"amount":39236.3,"timestamp":1744934391638},"delay":0,"floatShares":5956250,"shares":6662800,"eps":-20.530598,"marketStatus":"Market Closed","change":-0.16,"latestTime":"04-17 16:00:00 EDT","open":0.64,"high":0.6695,"low":0.6001,"amount":927802.04713512,"amplitude":0.088963,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-20.530598,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.7801,"preHourTrading":{"tag":"盘前","latestPrice":0.6551,"preClose":0.7801,"latestTime":"09:29 EDT","volume":111567,"amount":75662.31281775,"timestamp":1744896567220},"postHourTrading":{"tag":"盘后","latestPrice":0.6148,"preClose":0.6201,"latestTime":"19:59 EDT","volume":63320,"amount":39236.3,"timestamp":1744934391638},"volumeRatio":0.06003513109183986},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CDT\",,,,,undefined,":{"symbol":"CDT","floatShares":5956250,"roa":"-168.82%","roe":"--","lyrEps":-20.530598,"volumeRatio":0.06003513109183986,"shares":6662800,"dividePrice":0,"high":0.6695,"amplitude":0.088963,"preClose":0.7801,"low":0.6001,"week52Low":0.51,"pbRate":"-0.61","week52High":350,"institutionHeld":0,"latestPrice":0.6201,"eps":-20.530598,"divideRate":0,"volume":1466988,"delay":0,"ttmEps":-20.530598,"open":0.64,"prevYearClose":6.86,"prevWeekClose":0.9101,"prevMonthClose":0.781,"prevQuarterClose":0.781,"fiveDayClose":1.07,"twentyDayClose":0.8792,"sixtyDayClose":6.25},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CDT\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527114592","title":"BRIEF-Conduit Pharmaceuticals Announces Leadership Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2527114592","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527114592?lang=en_us&edition=fundamental","pubTime":"2025-04-16 20:40","pubTimestamp":1744807252,"startTime":"0","endTime":"0","summary":"BRIEF-Conduit Pharmaceuticals Announces Leadership ChangesApril 16 (Reuters) - Conduit Pharmaceuticals Inc CDT.O:CONDUIT PHARMACEUTICALS ANNOUNCES LEADERSHIP CHANGESCONDUIT PHARMACEUTICALS INC - APPOI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nTUA1RP5HL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDT","BK4121"],"gpt_icon":0},{"id":"2526698452","title":"BRIEF-Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For Vtama®","url":"https://stock-news.laohu8.com/highlight/detail?id=2526698452","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526698452?lang=en_us&edition=fundamental","pubTime":"2025-04-11 20:57","pubTimestamp":1744376238,"startTime":"0","endTime":"0","summary":"BRIEF-Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VtamaApril 11 (Reuters) - Conduit Pharmaceuticals Inc CDT.O:CONDUIT PHARMACEUTICALS ANNOUNCES NOVEL COCRYSTAL PATENT FILING FO","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250411:nFWN3QP1E8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","CDT"],"gpt_icon":0},{"id":"2526698716","title":"Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=2526698716","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526698716?lang=en_us&edition=fundamental","pubTime":"2025-04-11 20:30","pubTimestamp":1744374600,"startTime":"0","endTime":"0","summary":"Conduit Pharmaceuticals files next generation cocrystal patent for VTAMA  which the Company believes could be a superior asset with both inflammatory and autoimmune prospectives just as the drug approaches 2027 exclusivity expiration, positioning the Company for high-value licensing partnerships.This innovative approach differentiates Conduit's intellectual property from existing formulation patents, offering potential partners a next generation tapinarof asset with what the Company estimates to be extensive commercial viability. This comes at a critical juncture for VTAMA, a drug that has demonstrated blockbuster potential through Organon's $1.2 billion acquisition from Dermavant Sciences yet could face imminent generic competition upon exclusivity expiry in 2027. The timing is particularly strategic in the Company’s view, with tapinarof now entering clinical trials for cutaneous lupus and showing promise across multiple other inflammatory and autoimmune indications. Conduit's novel a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/conduit-pharmaceuticals-announces-novel-cocrystal-123000026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CDT","CDTTW","BK4121"],"gpt_icon":0},{"id":"2526669675","title":"Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2526669675","media":"THOMSON REUTERS","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526669675?lang=en_us&edition=fundamental","pubTime":"2025-04-10 20:30","pubTimestamp":1744288201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nTUA5D2YKG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CDT","BK4121"],"gpt_icon":0},{"id":"2526695845","title":"Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2526695845","media":"GlobeNewswire","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526695845?lang=en_us&edition=fundamental","pubTime":"2025-04-10 20:30","pubTimestamp":1744288200,"startTime":"0","endTime":"0","summary":"NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 10, 2025  -- Conduit Pharmaceuticals Inc.   today announced that its Board of Directors has authorized a share repurchase program under which the Company may purchase up to $1,000,000 of its outstanding common stock. The Directors believe that the market price of its common stock trades at prices that do not reflect their underlying value.Under the program, Conduit may repurchase shares from time to time through open market transactions or other methods in compliance with SEC Rule 10b-18. Purchases will be executed by The Benchmark Company, the Company's appointed broker, and will be subject to market conditions, corporate liquidity requirements, regulatory considerations, and other factors.The share repurchase program does not obligate the Company to acquire a particular amount of common stock and the Company will use its discretion to repurchase shares. The program has no fixed expiration date and may be adjusted or terminated at any ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/conduit-pharmaceuticals-announces-1-000-123000617.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4121","CDTTW","CDT"],"gpt_icon":0},{"id":"2525043461","title":"BRIEF-Conduit Pharmaceuticals Expands Partnership With Sarborg Limited","url":"https://stock-news.laohu8.com/highlight/detail?id=2525043461","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525043461?lang=en_us&edition=fundamental","pubTime":"2025-04-07 21:07","pubTimestamp":1744031227,"startTime":"0","endTime":"0","summary":"BRIEF-Conduit Pharmaceuticals Expands Partnership With Sarborg LimitedApril 7 (Reuters) - Conduit Pharmaceuticals Inc CDT.O:CONDUIT PHARMACEUTICALS EXPANDS PARTNERSHIP WITH SARBORG LIMITED TO LEVERAGE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nFWN3QL0YK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","CDT"],"gpt_icon":0},{"id":"2525043487","title":"Conduit expands parntership with Sarborg","url":"https://stock-news.laohu8.com/highlight/detail?id=2525043487","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525043487?lang=en_us&edition=fundamental","pubTime":"2025-04-07 20:50","pubTimestamp":1744030206,"startTime":"0","endTime":"0","summary":"Conduit Pharmaceuticals (CDT) entered into an additional license and use agreement with Sarborg to expand the scope of work on Conduit’s acquired A...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/conduit-expands-parntership-with-sarborg?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/conduit-expands-parntership-with-sarborg?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","CDT"],"gpt_icon":0},{"id":"2525107550","title":"Conduit Pharmaceuticals Expands Partnership With Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization","url":"https://stock-news.laohu8.com/highlight/detail?id=2525107550","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525107550?lang=en_us&edition=fundamental","pubTime":"2025-04-07 20:32","pubTimestamp":1744029132,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nFWN3QL0YK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","CDT"],"gpt_icon":0},{"id":"2525488220","title":"Conduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization","url":"https://stock-news.laohu8.com/highlight/detail?id=2525488220","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525488220?lang=en_us&edition=fundamental","pubTime":"2025-04-07 20:30","pubTimestamp":1744029000,"startTime":"0","endTime":"0","summary":"Conduit expands its partnership with Sarborg to apply advanced machine learning-driven analysis on clinical data from its AstraZeneca-acquired assets, aiming to uncover new insights and optimize development pathways.NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 07, 2025  -- Conduit Pharmaceuticals Inc.   today announces that it has entered into an additional license and use agreement  withSarborg Limited to expand the scope of work on Conduit’s acquired AstraZeneca assets, includingAZD1656, AZD5658, and AZD5904.Under the agreement,Sarborgwill apply its proprietarymachine learning algorithmsto conduct an in-depth analysis of Conduit’s clinical and safety data, with the goal of uncovering missed insights, identifying potential drug repurposing opportunities, and highlighting gaps in existing datasets. A key focus will be the re-evaluation of historical clinical trial data, including endpoints, to determine whether specific patient subgroups may have demonstrated therapeutic benefits,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/conduit-pharmaceuticals-expands-partnership-sarborg-123000246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CDT","CDTTW"],"gpt_icon":0},{"id":"2523949510","title":"Conduit Pharmaceuticals Inc - Secures Composition of Matter Patent From Uspto for Azd1656","url":"https://stock-news.laohu8.com/highlight/detail?id=2523949510","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523949510?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:35","pubTimestamp":1743424507,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QE0VM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","CDT"],"gpt_icon":0},{"id":"2523941750","title":"Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2523941750","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523941750?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:30","pubTimestamp":1743424200,"startTime":"0","endTime":"0","summary":"Conduit secures a composition of matter patent from the USPTO for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and strategic partnerships.NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 31, 2025  -- Conduit Pharmaceuticals Inc.   today announces that the United States Patent and Trademark Office  has granted the composition of matter patent for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune diseases, including Lupus and ANCA Vasculitis. With this critical composition of matter patent protection now secured, the Company is strategically positioned to advance AZD1656 into clinical development, with clinical trial plans now in final stages of preparation.Conduit is a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development. Conduit both acquires and funds the development of Phase 2-ready assets, building an integrated and adv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/conduit-pharmaceuticals-receives-u-patent-123000741.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CDT","CDTTW"],"gpt_icon":0},{"id":"2521747413","title":"Oxbridge / SurancePlus to Speak at Uncorrelated Puerto Rico on April 1st","url":"https://stock-news.laohu8.com/highlight/detail?id=2521747413","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521747413?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:00","pubTimestamp":1742817600,"startTime":"0","endTime":"0","summary":"GRAND CAYMAN, Cayman Islands, March  24, 2025  (GLOBE NEWSWIRE) -- Oxbridge Re Holdings Limited (Nasdaq: OXBR) (“Oxbridge Re”), together with its subsidiary SurancePlus, is engaged in the tokenization","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/24/3047770/0/en/Oxbridge-SurancePlus-to-Speak-at-Uncorrelated-Puerto-Rico-on-April-1st.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDT","OXBR","BK4121","BK4019"],"gpt_icon":0},{"id":"2520858184","title":"Conduit Pharmaceuticals provides R&D upgrade on AZD1656, AZD5658, AZD5904","url":"https://stock-news.laohu8.com/highlight/detail?id=2520858184","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520858184?lang=en_us&edition=fundamental","pubTime":"2025-03-19 20:37","pubTimestamp":1742387827,"startTime":"0","endTime":"0","summary":"Conduit Pharmaceuticals (CDT) provides an R&D update on the development progress of pipeline assets AZD1656, AZD5658, and AZD5904. The Company has ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/conduit-pharmaceuticals-provides-rd-upgrade-on-azd1656-azd5658-azd5904?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/conduit-pharmaceuticals-provides-rd-upgrade-on-azd1656-azd5658-azd5904?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","CDT"],"gpt_icon":0},{"id":"2520893691","title":"Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets Azd1656, Azd5658, and Azd5904","url":"https://stock-news.laohu8.com/highlight/detail?id=2520893691","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520893691?lang=en_us&edition=fundamental","pubTime":"2025-03-19 20:30","pubTimestamp":1742387401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nTUA2PXNRD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CDT","BK4121"],"gpt_icon":0},{"id":"2520892831","title":"Conduit Pharmaceuticals - Results for Study With Charles River Laboratories  Expected in Q2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2520892831","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520892831?lang=en_us&edition=fundamental","pubTime":"2025-03-19 20:30","pubTimestamp":1742387401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nTUA2PXNRD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","LU0390134368.USD","CDT","CRL","BK4585","BK4530","BK4588"],"gpt_icon":0},{"id":"2520181351","title":"Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904","url":"https://stock-news.laohu8.com/highlight/detail?id=2520181351","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520181351?lang=en_us&edition=fundamental","pubTime":"2025-03-19 20:30","pubTimestamp":1742387400,"startTime":"0","endTime":"0","summary":"Conduit Pharmaceuticals advances its pipeline with key progress in preclinical lupus studies for AZD5658, Phase IIa trial design for AZD1656, formulation optimization, and IP expansion, positioning the Company for near-term milestones and growth.At its research and development facility at Cambridge Science Park, Conduit is enhancing its IP portfolio and optimize the formulation of its pipeline assets. In the laboratory, the Company is evaluating the assets licensed through the AstraZeneca partnership and other assets of critical interest. Significant progress has also been made in securing intellectual property  protection for Conduit’s lead asset, AZD1656. Recent milestones include the grant of a composition-of-matter patent for the AZD1656 Cocrystals by the Japan Patent Office  and IP Australia, with pending applications at the USPTO and European Patent Office, and other global patent offices, expected to be approved early in the second quarter. In addition, Conduit is actively worki","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/conduit-pharmaceuticals-provides-research-development-123000754.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1481600234.SGD","BK4121","LU1481599808.USD","LU1487256676.USD","SLE","LU2463526074.USD","BK4077","BK4097","BK4585","PRGS","IP","BK4136","CDT","BK4588","LU2065732104.USD","CDTTW"],"gpt_icon":0},{"id":"2517102384","title":"Is Conduit Pharmaceuticals Inc. (CDT) the Best Micro Cap Stock to Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2517102384","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517102384?lang=en_us&edition=fundamental","pubTime":"2025-03-07 17:53","pubTimestamp":1741341217,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Best Micro Cap Stocks to Buy Now.In this article, we are going to take a look at where Conduit Pharmaceuticals Inc.  stands against the other micro cap stocks.Just as we overlook loose change, micro-cap stocks are often ignored for larger, more dominant enterprises. Investors trying to play safe ignore the fact that every strong stock was once a micro-cap stock. This niche segment of the market offers higher risk and, if successful, higher returns, particularly present in emerging industries where there is potential to outperform peers.Thus, with low price valuations by the investors, these stocks will continue to offer returns that surpass the returns from private equity fund investments. In view of this, we will take a look at some of the best","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/conduit-pharmaceuticals-inc-cdt-best-095337236.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QLD","SQQQ","USAW.SI","TSYW.SI",".IXIC","QID","NQmain","NVIW.SI","MNQmain","CDTTW","CDT","PSQ","USJW.SI","TQQQ","CDTDA","BK4121"],"gpt_icon":1},{"id":"2517164682","title":"Conduit Pharmaceuticals Gets Nasdaq Extension, Plans Capital Market Transfer","url":"https://stock-news.laohu8.com/highlight/detail?id=2517164682","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517164682?lang=en_us&edition=fundamental","pubTime":"2025-03-06 23:41","pubTimestamp":1741275704,"startTime":"0","endTime":"0","summary":"Conduit Pharmaceuticals  said Thursday that a Nasdaq hearing panel granted it an extension to meet listing requirements, with plans to transfer its shares to the Nasdaq Capital Market.The company said it must submit an application for the transfer by March 12 and meet all Nasdaq listing standards by March 31.Conduit said it had been at risk of delisting for not meeting requirements related to minimum bid price, market value of publicly held shares, and market value of listed securities. It regained compliance with the minimum bid price rule as of Feb. 26, according to the company.Following the transfer, the company expects to meet the continued listing requirement for publicly held shares above $1.0 million and believes it will satisfy the Nasdaq equity standard of stockholder's equity above $2.5 million before the March 31 deadline, though it cautioned that compliance is not assured.Shares of Conduit Pharmaceuticals were up nearly 4% in recent trading.Price: 1.11, Change: +0.04, Perce","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2095319765.USD","QLD","BK4112","USAW.SI","IE00BGHQF748.EUR","PSQ","BK4585","IE00BKPKM429.USD","USJW.SI","BK7104","TSYW.SI","CDTDA","BK4588","NQmain",".IXIC","LU2210149790.SGD","NDAQ","CDT.AU","MNQmain","IE00B64PRP62.GBP","TQQQ","NVIW.SI","CDT","BK4121","SQQQ","IE00B3QW5Z07.USD","QID","LU2210150020.SGD"],"gpt_icon":1},{"id":"2517316377","title":"Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel","url":"https://stock-news.laohu8.com/highlight/detail?id=2517316377","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517316377?lang=en_us&edition=fundamental","pubTime":"2025-03-06 22:35","pubTimestamp":1741271747,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nTUA619YD5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CDTDA","BK4121","CDT"],"gpt_icon":0},{"id":"2512866074","title":"BRIEF-Conduit Pharmaceuticals Files For Offering Of Up To $17.8 Million Of Shares Of Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2512866074","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512866074?lang=en_us&edition=fundamental","pubTime":"2025-02-19 23:25","pubTimestamp":1739978732,"startTime":"0","endTime":"0","summary":"BRIEF-Conduit Pharmaceuticals Files For Offering Of Up To $17.8 Million Of Shares Of Common Stock - SEC FilingFeb 19  - Conduit Pharmaceuticals Inc CDT.O:CONDUIT PHARMACEUTICALS FILES FOR OFFERING OF UP TO $17.8 MILLION OF SHARES OF COMMON STOCK - SEC FILINGSource text: [ID:n0001493152-25-007520]Further company coverage: CDT.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250219:nFWN3PA0J9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDT","BK4121"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":75,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CDT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-01-27","symbol":"CDT","defaultRemindTime":1737988200000,"type":"split","dateTimestamp":1737954000000,"forFactor":100,"toFactor":1,"ratio":100}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CDT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CDT\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CDT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CDT","date":"2025-04-17","current":-0.291968,"percent":0.859944,"low":-460.917103,"twenty":-47.947567,"median":-8.781761,"eighty":-0.581358,"high":-0.0799,"avg":-41.518424,"sd":89.834761,"marketCap":5197615},"quantilePoints":[{"date":"2023-10-13","current":-14.733381,"twenty":-17.829889,"median":-16.48141,"eighty":-15.432593,"marketCap":128180419},{"date":"2023-10-20","current":-14.483663,"twenty":-16.181748,"median":-14.691762,"eighty":-14.550255,"marketCap":126007869},{"date":"2023-10-27","current":-9.739015,"twenty":-15.882086,"median":-14.650142,"eighty":-14.017522,"marketCap":84729429},{"date":"2023-11-03","current":-12.652395,"twenty":-15.199522,"median":-14.483663,"eighty":-12.552508,"marketCap":110075840},{"date":"2023-11-10","current":-10.071973,"twenty":-14.799973,"median":-12.902114,"eighty":-10.821128,"marketCap":87626162},{"date":"2023-11-17","current":-9.745674,"twenty":-14.66679,"median":-12.152959,"eighty":-9.744342,"marketCap":84787364},{"date":"2023-11-24","current":-24.87973,"twenty":-14.683438,"median":-11.487043,"eighty":-9.941453,"marketCap":133977347},{"date":"2023-12-01","current":-63.281053,"twenty":-17.380396,"median":-12.694015,"eighty":-10.221804,"marketCap":340768471},{"date":"2023-12-08","current":-47.866438,"twenty":-32.992686,"median":-14.483663,"eighty":-10.372134,"marketCap":257760767},{"date":"2023-12-15","current":-96.544171,"twenty":-48.488431,"median":-14.650142,"eighty":-10.455207,"marketCap":519890360},{"date":"2023-12-22","current":-67.607963,"twenty":-67.878395,"median":-15.066339,"eighty":-10.588057,"marketCap":364068880},{"date":"2023-12-29","current":-66.255804,"twenty":-68.040654,"median":-16.106832,"eighty":-10.687945,"marketCap":356787502},{"date":"2024-01-05","current":-66.120588,"twenty":-67.716136,"median":-18.728875,"eighty":-10.787832,"marketCap":356059364},{"date":"2024-01-12","current":-60.576735,"twenty":-67.716136,"median":-27.854481,"eighty":-10.887719,"marketCap":326205716},{"date":"2024-01-19","current":-38.130891,"twenty":-67.526833,"median":-37.184379,"eighty":-11.204029,"marketCap":205334848},{"date":"2024-01-26","current":-38.942186,"twenty":-66.82371,"median":-38.942186,"eighty":-11.453747,"marketCap":209703674},{"date":"2024-02-02","current":-35.697004,"twenty":-66.30989,"median":-38.468931,"eighty":-11.886593,"marketCap":192228368},{"date":"2024-02-09","current":-43.742352,"twenty":-66.174674,"median":-38.266107,"eighty":-12.452621,"marketCap":235552565},{"date":"2024-02-16","current":-41.240857,"twenty":-65.71494,"median":-38.468931,"eighty":-12.702339,"marketCap":222082016},{"date":"2024-02-23","current":-38.266107,"twenty":-64.633212,"median":-38.468931,"eighty":-12.868818,"marketCap":206062986},{"date":"2024-03-01","current":-34.750493,"twenty":-63.362183,"median":-38.536539,"eighty":-13.634621,"marketCap":187131404},{"date":"2024-03-08","current":-35.83222,"twenty":-63.226967,"median":-38.198499,"eighty":-14.483663,"marketCap":192956506},{"date":"2024-03-15","current":-42.998664,"twenty":-62.118196,"median":-38.266107,"eighty":-14.550255,"marketCap":231547807},{"date":"2024-03-22","current":-46.649494,"twenty":-58.954144,"median":-38.80697,"eighty":-14.650142,"marketCap":251207527},{"date":"2024-03-28","current":-48.272085,"twenty":-56.303911,"median":-39.212618,"eighty":-14.66679,"marketCap":259945180},{"date":"2024-04-05","current":-44.215608,"twenty":-55.411486,"median":-39.753482,"eighty":-14.799973,"marketCap":238101047},{"date":"2024-04-12","current":-43.13388,"twenty":-54.194543,"median":-40.294346,"eighty":-15.199522,"marketCap":232275945},{"date":"2024-04-19","current":-40.993558,"twenty":-49.732418,"median":-40.835209,"eighty":-15.882086,"marketCap":220750312},{"date":"2024-04-26","current":-427.79731,"twenty":-59.765439,"median":-41.117207,"eighty":-16.930903,"marketCap":228871561},{"date":"2024-05-03","current":-412.617406,"twenty":-65.03886,"median":-41.781721,"eighty":-19.959046,"marketCap":220750312},{"date":"2024-05-10","current":-419.517363,"twenty":-67.256401,"median":-42.187369,"eighty":-24.87973,"marketCap":224441789},{"date":"2024-05-17","current":-89.879435,"twenty":-68.824906,"median":-42.728232,"eighty":-26.06963,"marketCap":217058835},{"date":"2024-05-24","current":-90.49086,"twenty":-78.722712,"median":-42.998664,"eighty":-31.234879,"marketCap":218535426},{"date":"2024-05-31","current":-91.713709,"twenty":-86.822311,"median":-42.998664,"eighty":-32.85747,"marketCap":221488608},{"date":"2024-06-07","current":-85.905174,"twenty":-88.962298,"median":-43.539528,"eighty":-34.750493,"marketCap":207460996},{"date":"2024-06-14","current":-61.753897,"twenty":-87.739448,"median":-43.80996,"eighty":-34.966839,"marketCap":149135662},{"date":"2024-06-21","current":-44.634005,"twenty":-87.066881,"median":-44.080392,"eighty":-35.264314,"marketCap":107791122},{"date":"2024-06-28","current":-31.182661,"twenty":-86.822311,"median":-44.080392,"eighty":-35.020925,"marketCap":75306126},{"date":"2024-07-05","current":-19.568648,"twenty":-86.822311,"median":-43.80996,"eighty":-32.160941,"marketCap":47258285},{"date":"2024-07-12","current":-8.865658,"twenty":-86.822311,"median":-43.336704,"eighty":-24.87973,"marketCap":21410565},{"date":"2024-07-15","current":-8.024949,"twenty":-86.822311,"median":-43.13388,"eighty":-24.87973,"marketCap":19380253},{"date":"2024-08-02","current":-6.267103,"twenty":-86.638884,"median":-43.066272,"eighty":-20.630864,"marketCap":15135054},{"date":"2024-08-09","current":-5.19711,"twenty":-85.477177,"median":-42.998664,"eighty":-16.282943,"marketCap":12551021},{"date":"2024-08-16","current":-2.669983,"twenty":-83.616666,"median":-42.79584,"eighty":-14.799973,"marketCap":15197543},{"date":"2024-08-23","current":-2.782989,"twenty":-82.833276,"median":-42.457801,"eighty":-14.483663,"marketCap":15840775},{"date":"2024-08-30","current":-2.194345,"twenty":-81.616333,"median":-41.849329,"eighty":-12.669043,"marketCap":12490211},{"date":"2024-09-06","current":-2.099892,"twenty":-79.777396,"median":-41.511289,"eighty":-11.403804,"marketCap":11952585},{"date":"2024-09-13","current":-2.329278,"twenty":-74.503975,"median":-40.970425,"eighty":-10.48817,"marketCap":13258248},{"date":"2024-09-20","current":-2.255065,"twenty":-70.177065,"median":-40.294346,"eighty":-9.745674,"marketCap":12835828},{"date":"2024-09-27","current":-2.172418,"twenty":-69.636202,"median":-39.888698,"eighty":-9.018515,"marketCap":12365405},{"date":"2024-10-04","current":-1.66136,"twenty":-68.960122,"median":-39.618266,"eighty":-8.024949,"marketCap":9456462},{"date":"2024-10-11","current":-1.72714,"twenty":-68.284042,"median":-38.942186,"eighty":-5.597593,"marketCap":9830881},{"date":"2024-10-18","current":-1.71196,"twenty":-68.148827,"median":-38.401323,"eighty":-2.782989,"marketCap":9744476},{"date":"2024-10-25","current":-2.062785,"twenty":-67.607963,"median":-38.130891,"eighty":-2.68685,"marketCap":11741374},{"date":"2024-10-31","current":-1.791696,"twenty":-67.49979,"median":-37.590027,"eighty":-2.642322,"marketCap":10198332},{"date":"2024-11-08","current":-1.699632,"twenty":-66.607365,"median":-37.522419,"eighty":-2.434525,"marketCap":9674307},{"date":"2024-11-15","current":-0.683034,"twenty":-66.282847,"median":-37.18438,"eighty":-2.341422,"marketCap":9657424},{"date":"2024-11-22","current":-0.732446,"twenty":-66.147631,"median":-36.711124,"eighty":-2.250005,"marketCap":11097296},{"date":"2024-11-29","current":-0.724301,"twenty":-65.88513,"median":-36.035044,"eighty":-2.191309,"marketCap":10973878},{"date":"2024-12-06","current":-0.642842,"twenty":-65.728158,"median":-35.697004,"eighty":-2.136324,"marketCap":9739703},{"date":"2024-12-13","current":-0.648697,"twenty":-65.557968,"median":-34.885709,"eighty":-2.104952,"marketCap":9828408},{"date":"2024-12-20","current":-0.518958,"twenty":-64.227565,"median":-32.405511,"eighty":-2.070881,"marketCap":7862726},{"date":"2024-12-27","current":-0.460417,"twenty":-63.362183,"median":-30.829231,"eighty":-1.971833,"marketCap":6975772},{"date":"2025-01-03","current":-0.598858,"twenty":-63.25401,"median":-24.87973,"eighty":-1.919522,"marketCap":9073299},{"date":"2025-01-10","current":-0.648697,"twenty":-63.145837,"median":-19.568648,"eighty":-1.895806,"marketCap":9828408},{"date":"2025-01-17","current":-0.583827,"twenty":-61.753897,"median":-17.605142,"eighty":-1.8334,"marketCap":8845567},{"date":"2025-01-24","current":-0.395547,"twenty":-60.812167,"median":-15.982791,"eighty":-1.791603,"marketCap":5992932},{"date":"2025-01-31","current":-0.201729,"twenty":-57.331553,"median":-15.066339,"eighty":-1.741555,"marketCap":3056394},{"date":"2025-02-07","current":-0.122619,"twenty":-55.654875,"median":-14.650142,"eighty":-1.697038,"marketCap":1857808},{"date":"2025-02-14","current":-0.128948,"twenty":-55.330356,"median":-14.483663,"eighty":-1.649553,"marketCap":1953695},{"date":"2025-02-21","current":-0.09414,"twenty":-55.13826,"median":-12.778777,"eighty":-0.882703,"marketCap":1426317},{"date":"2025-02-28","current":-0.088602,"twenty":-53.010523,"median":-12.402677,"eighty":-0.73059,"marketCap":1342416},{"date":"2025-03-07","current":-0.08702,"twenty":-50.521832,"median":-11.403804,"eighty":-0.711674,"marketCap":1318444},{"date":"2025-03-14","current":-0.0799,"twenty":-49.678331,"median":-10.737889,"eighty":-0.666568,"marketCap":1210571},{"date":"2025-03-21","current":-0.211359,"twenty":-49.502551,"median":-10.405763,"eighty":-0.647115,"marketCap":3202300},{"date":"2025-03-28","current":-0.184627,"twenty":-48.933528,"median":-9.908824,"eighty":-0.629809,"marketCap":2797277},{"date":"2025-04-04","current":-0.256525,"twenty":-48.406557,"median":-9.739015,"eighty":-0.621391,"marketCap":4566652},{"date":"2025-04-11","current":-0.400469,"twenty":-48.109826,"median":-8.942087,"eighty":-0.595694,"marketCap":7129147},{"date":"2025-04-17","current":-0.291968,"twenty":-47.947567,"median":-8.781761,"eighty":-0.581358,"marketCap":5197615}],"updateTime":1745054165200}}}